Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

References

• Brotherton JML, Tabrizi SN, Phillips S, et al. Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. Int J Cancer. 2017;141(8):1576–1584. doi:10.1002/ijc.3087128677147
   PubMed Web of Science ®Google Scholar
• Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–664. doi:10.1097/OLQ.000000000000019325299412
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–1799. doi:10.1086/65732121067372
   PubMed Web of Science ®Google Scholar
• Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486–494. doi:10.1093/aje/kwg17112936904
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814. doi:10.1086/59707119199546
   PubMed Web of Science ®Google Scholar
• Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39. doi:10.1186/1471-2334-13-3923347441
   PubMed Web of Science ®Google Scholar
• Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118(6–7):450–454. doi:10.1111/j.1600-0463.2010.02619.x20553527
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.3071628369882
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. doi:10.1016/S1470-2045(10)70230-820952254
   PubMed Web of Science ®Google Scholar
• D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–1956. doi:10.1056/NEJMoa06549717494927
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–789. doi:10.1016/S1470-2045(10)70017-620451455
   PubMed Web of Science ®Google Scholar
• Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500–1510. doi:10.1093/jnci/92.18.150010995805
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Toh ZQ, Licciardi PV, Russell FM, Garland SM, Batmunkh T, Mulholland EK. Cervical cancer prevention through HPV vaccination in low- and middle-income countries in Asia. Asian Pac J Cancer Prev. 2017;18(9):2339–2343. doi:10.22034/APJCP.2017.18.9.233928950675
   PubMedGoogle Scholar
• Howard N, Gallagher KE, Mounier-Jack S, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22–25. doi:10.1016/j.pvr.2017.06.00329179865
   PubMed Web of Science ®Google Scholar
• Bruni L, Barrionuevo-Rosas L, Albero GAM, et al. Human papillomavirus and related diseases in Asia. Summary report. ICO Information Centre on HPV and Cancer (HPV Information Centre); 2018 Accessed 417, 2015.
   Google Scholar
• Garcon N, Wettendorff M, Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther. 2011;11(5):667–677. doi:10.1517/14712598.2011.57362421457083
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705–719. doi:10.4161/hv.5.10.951819684472
   PubMed Web of Science ®Google Scholar
• Einstein MH, Levin MJ, Chatterjee A, et al. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014;10(12):3455–3465. doi:10.4161/hv.3611725483700
   PubMed Web of Science ®Google Scholar
• Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. doi:10.1056/NEJMoa06174117494925
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943. doi:10.1056/NEJMoa06176017494926
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Future I/II Study Group, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 341;2010:c3493. doi:10.1136/bmj.c349320647284
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99. doi:10.1016/S1470-2045(11)70286-822075171
   PubMed Web of Science ®Google Scholar
• Mensah FA, Mehta MR, Lewis JS Jr., Lockhart AC. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal intraepithelial neoplasia and anal cancer. Oncologist. 2016;21(4):453–460. doi:10.1634/theoncologist.2015-007526961923
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196–204. doi:10.1016/j.ygyno.2017.04.00428442134
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Galaj A, Spaczynski M, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017;6(11):2723–2731. doi:10.1002/cam4.115528984053
   PubMed Web of Science ®Google Scholar
• Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32Pt A):4768–4773. doi:10.1016/j.vaccine.2017.12.07929325819
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135–2145. doi:10.1542/peds.2006-046117079588
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564–571. doi:10.1016/j.jadohealth.2007.02.01517531764
   PubMed Web of Science ®Google Scholar
• Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44(1):33–40. doi:10.1016/j.jadohealth.2008.10.00219101456
   PubMed Web of Science ®Google Scholar
• Toh ZQ, Licciardi PV, Fong J, et al. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Vaccine. 2015;33(39):5042–5050. doi:10.1016/j.vaccine.2015.07.10226271829
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group Of Experts on immunization, April 2014 – conclusions and recommendations. Relevé Épidémiologique Hebdomadaire. 2014;89(21):221–236.24864348
   PubMedGoogle Scholar
• Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926–935. doi:10.1086/59730719236279
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199(7):936–944. doi:10.1086/59730919236277
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314. doi:10.1016/S0140-6736(09)61248-419586656
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–1302. doi:10.1016/S1473-3099(17)30468-128965955
   PubMed Web of Science ®Google Scholar
• Barzon L, Squarzon L, Masiero S, et al. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine. 2014;32(41):5357–5362. doi:10.1016/j.vaccine.2014.07.01425045814
   PubMed Web of Science ®Google Scholar
• Garland SM, Cornall AM, Brotherton JML, et al. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018;36(23):3221–3230. doi:10.1016/j.vaccine.2018.04.08029724506
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011;7(12):1359–1373. doi:10.4161/hv.7.12.1828222048172
   PubMed Web of Science ®Google Scholar
• Godi A, Bissett SL, Miller E, Beddows S. Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix(R) or Gardasil(R) vaccine. PLoS One. 2015;10(10):e0140926. doi:10.1371/journal.pone.014092626495976
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011;29(11):2011–2014. doi:10.1016/j.vaccine.2011.01.00121241731
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723. doi:10.1056/NEJMoa140504425693011
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159. doi:10.1016/S0140-6736(17)31821-428886907
   PubMed Web of Science ®Google Scholar
• Garland SM, Pitisuttithum P, Ngan HYS, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218(1):95–108. doi:10.1093/infdis/jiy13329767739
   PubMed Web of Science ®Google Scholar
• Ruiz-Sternberg AM, Moreira ED Jr., Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 2018;5:63–74. doi:10.1016/j.pvr.2017.12.00429269325
   PubMed Web of Science ®Google Scholar
• Iwata S, Murata S, Rong Han S, Wakana A, Sawata M, Tanaka Y. Safety and Immunogenicity of a 9-valent human papillomavirus vaccine administered to 9- to 15-year-old Japanese girls. Jpn J Infect Dis. 2017;70(4):368–373. doi:10.7883/yoken.JJID.2016.29928003597
   PubMed Web of Science ®Google Scholar
• Van Damme P, Meijer C, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–4212. doi:10.1016/j.vaccine.2016.06.05627354258
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil(R) in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34(9):992–998. doi:10.1097/INF.000000000000077326090572
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Ed M Jr., Samakoses R, et al. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother. 2015;11(6):1306–1312. doi:10.1080/21645515.2015.100981926086587
   PubMed Web of Science ®Google Scholar
• Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1):e28–39. doi:10.1542/peds.2014-374526101366
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother. 2015;11(6):1313–1322. doi:10.1080/21645515.2015.101201025912208
   PubMed Web of Science ®Google Scholar
• Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine. 2017;35(37):5050–5057. doi:10.1016/j.vaccine.2017.07.01728789851
   PubMed Web of Science ®Google Scholar
• Castellsague X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–6901. doi:10.1016/j.vaccine.2015.06.08826144901
   PubMed Web of Science ®Google Scholar
• Garland SM, Cheung TH, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–6864. doi:10.1016/j.vaccine.2015.08.05926411885
   PubMed Web of Science ®Google Scholar
• Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya JM, Gershwin ME. Original antigenic sin: a comprehensive review. J Autoimmun. 2017;83:12–21. doi:10.1016/j.jaut.2017.04.00828479213
   PubMed Web of Science ®Google Scholar
• Van Damme P, Bonanni P, Bosch FX, et al. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016;34(6):757–761. doi:10.1016/j.vaccine.2015.12.06326772631
   PubMed Web of Science ®Google Scholar
• Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316(22):2411–2421. doi:10.1001/jama.2016.1761527893068
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz L. se of a 2-dose schedule for Human Papillomavirus Vaccination — updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–1408. doi:10.15585/mmwr.mm6549a527977643
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Gardasil 9. Summary of product characteristics; 2018 Accessed 1029, 2018.
   Google Scholar
• National Centre For Immunisation Research and Surveillance. Human papillomavirus (HPV) vaccines for Australians: information for immunisation providers; 2018 Accessed 1029, 2018.
   Google Scholar
• Moreira ED Jr., Block SL, Ferris D, et al. Safety profile of the 9-Valent HPV vaccine: a combined analysis of 7 phase iii clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-438727422279
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015;34(6):627–634. doi:10.1097/INF.000000000000069425831420
   PubMed Web of Science ®Google Scholar
• Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136(3): E563-E572. doi:10.1542/peds.2015-0573
   Web of Science ®Google Scholar
• Luxembourg A, Kjaer SK, Nygard M, et al. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Contemp Clin Trials. 2017;52:54–61. doi:10.1016/j.cct.2016.10.00627777126
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Gee J, Chesson H, Stokley S. Ten years of human papillomavirus vaccination in the United States. Acad Pediatr. 2018;18(2S):S3–S10. doi:10.1016/j.acap.2017.09.01429502635
   PubMed Web of Science ®Google Scholar
• Ward K, Quinn H, Menzies R, McIntyre P. A history of adolescent school based vaccination in Australia. Commun Dis Intell Q Rep. 2013;37(2):E168–E174.24168091
   PubMedGoogle Scholar
• McClure CA, MacSwain MA, Morrison H, Sanford CJ. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada. Vaccine. 2015;33(15):1786–1790. doi:10.1016/j.vaccine.2015.02.04725731789
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–2092. doi:10.1016/S0140-6736(11)60551-521684381
   PubMed Web of Science ®Google Scholar
• Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination. J Infect Dis. 2018. doi:10.1093/infdis/jiy075
   Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645–1651. doi:10.1093/infdis/jis59023087430
   PubMed Web of Science ®Google Scholar
• Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23:41. doi:10.2807/1560-7917.ES.2018.23.41.1700737
   Google Scholar
• Brotherton JM, Hawkes D, Sultana F, et al. Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: a new tool for monitoring vaccine impact. Vaccine. 2019;37(3):412–416. doi:10.1016/j.vaccine.2018.11.07530551987
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2018;4(1):E19–E27. doi:10.1016/S2468-2667(18)30183-X
   Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Trudeau G. Advisory report on the Human Papillomavirus (HPV) Vaccination Schedule. National Institute of Public Health of Quebec; 2018 Available from: https://www.inspq.qc.ca/sites/default/files/publications/2458_papillomavirus_vaccination_schedule.pdf
   Google Scholar
• Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018;36(46):7017–7024. doi:10.1016/j.vaccine.2018.09.05730314913
   PubMed Web of Science ®Google Scholar
• Toh ZQ, Russell FM, Reyburn R, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV Vaccine: a prospective cohort study. Clin Infect Dis. 2017;64(7):852–859. doi:10.1093/cid/ciw86528034886
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Boulianne N, et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccin Immunother. 2015;11(3):732–738. doi:10.1080/21645515.2015.101157025714044
   PubMed Web of Science ®Google Scholar
• Mennini FS, Bonanni P, Bianic F, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15:11. doi:10.1186/s12962-017-0073-828701899
   PubMed Web of Science ®Google Scholar
• Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):85–98. doi:10.1080/14737167.2016.120808727366939
   PubMed Web of Science ®Google Scholar
• Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113(18):5107–5112. doi:10.1073/pnas.151552811327091978
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–304.25811679
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–e463. doi:10.1016/S2214-109X(16)30099-727340003
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines; 2018 Accessed 107th, 2018.
   Google Scholar
• ClinicalTrials.gov. A dose reduction immunobridging and safety study of two HPV vaccines in tanzanian girls (DoRIS); 2018 Accessed 117th, 2018.
   Google Scholar
• The World Health Organization. Vaccine in national immunization programme update; 2018 [Updated 10 2018]. Accessed 1227th, 2018.
   Google Scholar